Haddonfield NJ, March 16, 2018–Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced it has been awarded a Phase 1 Small Business Technology Transfer (“STTR”) Award by the National Cancer Institute (“NCI”) of the National Institute for Health (“NIH”).
The $300,000 award was granted to Linnaeus in collaboration with one of its scientific cofounders, Todd Ridky, M.D., Ph.D., Assistant Professor of Dermatology at the University of Pennsylvania Perelman School of Medicine, after a highly competitive peer review process. The award will help fund the early development of its lead compound, LNS8801, which targets a G protein-coupled receptor, known as GPER, for the treatment of various cancers.
“This award provides a strong peer-reviewed validation of the core science that is the basis of LNS8801 and its target GPER,” said Patrick Mooney, M.D., chief executive officer of Linnaeus. “This money will allow us to further develop GPER agonists as a potentially safe and effective therapeutic for the treatment of various cancers, including melanoma, pancreas, lung and colon cancers, among other. We plan to aggressively develop GPER agonists, and we hope to continue our relationship with NCI over the long term.”
Linnaeus Therapeutics, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics that target a novel G protein-coupled receptor, known as GPER, or GPR30. The company was launched through the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures. Its lead molecule, LNS8801, is in the final stages of preclinical development. The company expects to begin its phase 1 clinical program in the summer of 2019. In addition to developing GPER agonists, Linnaeus is also currently focusing on developing small molecules that activate other G protein-coupled receptors to engage tumor-suppressive cellular signaling pathways.
Chief Executive Officer